A Director at TherapeuticsMD (NASDAQ: TXMD) is Buying Shares

By Carrie Williams

Today, a Director at TherapeuticsMD (TXMDResearch Report), Cooper Collins, bought shares of TXMD for $99.6K.

This recent transaction increases Cooper Collins’ holding in the company by 83.33% to a total of $218.5K. In addition to Cooper Collins, one other TXMD executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on TherapeuticsMD’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.95 million and GAAP net loss of $39.51 million. In comparison, last year the company earned revenue of $3.77 million and had a GAAP net loss of $24.4 million. Currently, TherapeuticsMD has an average volume of 5.7M. The Company has a Price to Book ratio of 13.1553.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $14.25, reflecting a 338.5% upside. Three different firms, including Cantor Fitzgerald and Noble Financial, currently also have a Buy rating on the stock.

The insider sentiment on TherapeuticsMD has been neutral according to 33 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.